Results 261 to 270 of about 28,483 (297)
Some of the next articles are maybe not open access.

A patient with anaphylaxis after alteplase infusion

Journal of Clinical Neuroscience, 2012
Anaphylaxis to alteplase is a rare but reported complication of intravenous thrombolysis. We report a patient with a documented episode of anaphylaxis that occurred following an initial bolus and a subsequent delayed infusion of alteplase for thrombolysis of acute ischaemic stroke.
Robert J. Heddle   +8 more
openaire   +4 more sources

Alteplase for Hemodialysis Access Graft Thrombolysis

Journal of Vascular and Interventional Radiology, 2002
To evaluate the efficacy and safety of alteplase, a recombinant tissue plasminogen activator, in hemodialysis access graft thrombolysis.From November 1999 to May 2001, 68 episodes of occlusion in 50 grafts (in 49 patients) were included in the study.
Kelekis Da   +7 more
openaire   +3 more sources

Alteplase: Pleural Effusion (Parapneumonic)

Hospital Pharmacy, 2003
Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses.
Joyce A. Generali, Dennis J. Cada
openaire   +2 more sources

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial

The Lancet, 2023
Yongjun Wang   +64 more
semanticscholar   +1 more source

Intravenous alteplase for acute ischaemic stroke [PDF]

open access: possibleExpert Opinion on Pharmacotherapy, 2005
Thrombolysis with intravenous alteplase is the only validated and approved treatment for acute ischaemic stroke. It is currently licensed for use within 3 h of stroke onset. This treatment improves functional outcome without increasing mortality, although it can initially cause a devastating intracerebral haemorrhage. Risk factors for this complication
openaire   +2 more sources

What is the future for alteplase in stroke?

Inpharma Weekly, 1998
Limited clinical evidence supports the use of IV alteplase as thrombolytic therapy for patients with acute ischaemic stroke. Results from the US National Institute of Neurological Disorders and Stroke (NINDS) trial indicated that IV alteplase 0.9 mg/kg improved patient outcome when administered within 3 hours of onset of stroke symptoms.*Nevertheless ...
openaire   +2 more sources

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial

The Lancet, 2022
B. Menon   +254 more
semanticscholar   +1 more source

Alteplase for ischaemic stroke—responses

The Lancet, 2014
William Whiteley   +5 more
openaire   +6 more sources

Alteplase activity

American Journal of Health-System Pharmacy, 2001
L C, Vermeulen   +2 more
openaire   +2 more sources

Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial

Lancet Neurology, 2022
C. E. Kvistad   +15 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy